domestic pharma / capability
Par parti pris · 1 takes across the edition
医药魔方 ByDrug (RNA editing) · China · China's in-vivo gene-editing pipeline reaches the clinic
Domestic framing positions Huida's in-brain CRISPR RNA edit as a Chinese-led global first and the second CRISPR RNA-editing therapy worldwide to enter human testing, emphasising China's depth in gene-editing + cell-therapy and gene-editing + stem-cell platforms.
“全球首个脑内RNA疗法，实现CRISPR治疗历史性突破 (World's first in-brain RNA therapy, a historic CRISPR treatment breakthrough).”